Analysts Set Medtronic (MDT) Target Price at $90.85

Medtronic (NYSE:MDT) has earned a consensus rating of “Buy” from the twenty-five brokerages that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and sixteen have assigned a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $90.85.

A number of equities analysts recently weighed in on the company. Morgan Stanley decreased their price objective on Medtronic from $95.00 to $90.00 and set an “equal weight” rating on the stock in a report on Thursday, March 29th. Oppenheimer restated a “buy” rating on shares of Medtronic in a research report on Tuesday, March 20th. Citigroup restated a “buy” rating and set a $93.00 price target (down from $100.00) on shares of Medtronic in a research report on Thursday, February 22nd. TheStreet lowered Medtronic from a “b” rating to a “c+” rating in a research report on Tuesday, February 20th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $92.00 price target on shares of Medtronic in a research report on Wednesday, February 14th.

In other news, SVP Carol A. Surface sold 24,479 shares of Medtronic stock in a transaction that occurred on Monday, March 5th. The stock was sold at an average price of $78.18, for a total value of $1,913,768.22. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director James T. Lenehan sold 1,306 shares of Medtronic stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of $83.56, for a total value of $109,129.36. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of the company. We Are One Seven LLC bought a new stake in shares of Medtronic during the fourth quarter valued at approximately $104,000. Blue Chip Partners Inc. bought a new stake in shares of Medtronic during the third quarter valued at approximately $118,000. BB&T Investment Services Inc. boosted its position in shares of Medtronic by 147.6% during the fourth quarter. BB&T Investment Services Inc. now owns 1,518 shares of the medical technology company’s stock valued at $126,000 after purchasing an additional 905 shares in the last quarter. Barrett Asset Management LLC boosted its position in shares of Medtronic by 856.0% during the fourth quarter. Barrett Asset Management LLC now owns 1,826 shares of the medical technology company’s stock valued at $147,000 after purchasing an additional 1,635 shares in the last quarter. Finally, SevenBridge Financial Group LLC boosted its position in shares of Medtronic by 76.2% during the third quarter. SevenBridge Financial Group LLC now owns 2,197 shares of the medical technology company’s stock valued at $171,000 after purchasing an additional 950 shares in the last quarter. Hedge funds and other institutional investors own 81.20% of the company’s stock.

Shares of NYSE MDT traded down $0.10 during trading hours on Friday, reaching $79.90. 3,690,928 shares of the stock traded hands, compared to its average volume of 4,645,961. The stock has a market cap of $108,294.30, a price-to-earnings ratio of 17.37, a P/E/G ratio of 2.38 and a beta of 0.94. The company has a current ratio of 2.43, a quick ratio of 2.09 and a debt-to-equity ratio of 0.51. Medtronic has a 52-week low of $76.41 and a 52-week high of $89.72.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, February 20th. The medical technology company reported $1.17 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.01. The company had revenue of $7.37 billion for the quarter, compared to analysts’ expectations of $7.20 billion. Medtronic had a return on equity of 12.65% and a net margin of 9.44%. Medtronic’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period last year, the firm posted $1.12 EPS. analysts forecast that Medtronic will post 4.74 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 13th. Stockholders of record on Friday, March 23rd were given a $0.46 dividend. The ex-dividend date of this dividend was Thursday, March 22nd. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.30%. Medtronic’s dividend payout ratio is currently 40.00%.

ILLEGAL ACTIVITY WARNING: This article was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/04/22/analysts-set-medtronic-mdt-target-price-at-90-85.html.

About Medtronic

Medtronic plc manufactures and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. The company's Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software.

Analyst Recommendations for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply